CRIS Current Research Information System

ZAMAGNI, ELENA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 12.237
NA - Nord America 10.725
EU - Europa 7.504
SA - Sud America 709
AF - Africa 653
OC - Oceania 26
Continente sconosciuto - Info sul continente non disponibili 4
Totale 31.858
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.564
CN - Cina 3.435
SG - Singapore 3.158
VN - Vietnam 3.128
IT - Italia 1.818
GB - Regno Unito 1.486
DE - Germania 890
SE - Svezia 769
HK - Hong Kong 736
FR - Francia 522
IN - India 508
BR - Brasile 498
KR - Corea 432
NL - Olanda 370
RU - Federazione Russa 370
IE - Irlanda 262
UA - Ucraina 220
FI - Finlandia 219
JP - Giappone 203
CI - Costa d'Avorio 188
ZA - Sudafrica 156
EE - Estonia 101
TG - Togo 101
SC - Seychelles 99
AR - Argentina 94
PH - Filippine 87
AT - Austria 75
CA - Canada 74
BG - Bulgaria 70
TH - Thailandia 68
BD - Bangladesh 66
CH - Svizzera 65
ID - Indonesia 57
ES - Italia 55
MX - Messico 53
BE - Belgio 49
PL - Polonia 47
TR - Turchia 47
JO - Giordania 45
IQ - Iraq 44
EC - Ecuador 35
TW - Taiwan 33
SA - Arabia Saudita 28
EG - Egitto 24
CZ - Repubblica Ceca 23
IR - Iran 23
AU - Australia 22
CO - Colombia 22
PK - Pakistan 22
NG - Nigeria 21
GR - Grecia 19
CL - Cile 18
UZ - Uzbekistan 16
LB - Libano 15
MA - Marocco 15
MY - Malesia 15
IL - Israele 14
VE - Venezuela 12
KE - Kenya 11
LT - Lituania 11
RO - Romania 11
TN - Tunisia 11
PY - Paraguay 9
UY - Uruguay 9
DO - Repubblica Dominicana 8
AL - Albania 7
DZ - Algeria 7
KZ - Kazakistan 7
NP - Nepal 7
OM - Oman 7
PT - Portogallo 7
AZ - Azerbaigian 6
HR - Croazia 6
PE - Perù 6
RS - Serbia 6
AE - Emirati Arabi Uniti 5
ET - Etiopia 5
GT - Guatemala 5
HN - Honduras 5
BO - Bolivia 4
CY - Cipro 4
KG - Kirghizistan 4
LV - Lettonia 4
QA - Qatar 4
BZ - Belize 3
GH - Ghana 3
HU - Ungheria 3
MK - Macedonia 3
NO - Norvegia 3
SN - Senegal 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AO - Angola 2
BY - Bielorussia 2
CR - Costa Rica 2
GE - Georgia 2
JM - Giamaica 2
LA - Repubblica Popolare Democratica del Laos 2
MN - Mongolia 2
MT - Malta 2
NC - Nuova Caledonia 2
Totale 31.820
Salva come PNG Salva come JPEG
Città #
Singapore 2.211
Ashburn 1.260
Southend 1.229
Fairfield 1.030
Hefei 908
Chandler 841
Ho Chi Minh City 719
Hong Kong 704
Hanoi 612
Woodbridge 483
Seattle 447
San Jose 443
Bologna 410
Wilmington 410
Houston 405
Seoul 393
Dallas 380
Beijing 374
Cambridge 351
Ann Arbor 345
Princeton 310
Dong Ket 286
Santa Clara 284
Dublin 258
Boardman 247
Lauterbourg 210
Abidjan 188
Los Angeles 175
Tokyo 167
Helsinki 159
New York 155
Milan 152
Nanjing 121
Jacksonville 117
Council Bluffs 115
Westminster 113
Haiphong 108
Berlin 103
Padova 103
Lomé 101
Frankfurt am Main 91
Bengaluru 88
Buffalo 85
Bremen 81
Da Nang 81
Munich 78
Jinan 75
Guangzhou 74
San Diego 69
Shanghai 69
Sofia 68
Redondo Beach 64
Turin 64
Tianjin 63
Shenyang 61
Saint Petersburg 60
Hyderabad 58
Changsha 56
São Paulo 52
Redwood City 51
Amsterdam 49
Chicago 49
Rome 49
Amman 45
Brussels 45
Florence 45
Redmond 44
Lappeenranta 43
Nuremberg 43
Zhengzhou 42
Nanchang 41
Shenzhen 40
Vienna 40
Bern 39
Johannesburg 38
Can Tho 37
London 37
Jakarta 36
Falls Church 33
Hangzhou 33
Hải Dương 33
Hebei 32
Biên Hòa 31
Warsaw 31
Falkenstein 30
Paris 30
Wuhan 28
Fabriano 27
Medford 27
Orem 27
Des Moines 26
Jiaxing 26
Phoenix 26
Quận Bình Thạnh 26
Salsomaggiore Terme 26
Toronto 26
Dongguan 24
Tongling 24
Washington 24
Ha Long 23
Totale 20.190
Salva come PNG Salva come JPEG
Nome #
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma 706
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease 338
A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. 308
BoBafit: A copy number clustering tool designed to refit and recalibrate the baseline region of tumors’ profiles 291
Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment 265
Prediction of response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed multiple myeloma by gene expression profiling (gep) 250
Peripheral neuropathy induced by subcutaneous bortezomib-based induction therapy for newly diagnosed multiple myeloma. 249
Positron emission tomography with computed tomography-based diagnosis of massive extramedullary progression in a patient with high-risk multiple myeloma. 246
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes 232
A NEW RISK STRATIFICATION STRATEGY IN NEWLY DIAGNOSED MULTIPLE MYELOMA: AN ANALYSIS ON MATURE DATA FROM EUROPEAN CLINICAL TRIALS WITHIN THE HARMONY BIG DATA PLATFORM 232
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD) 227
A new risk stratification model (R2-ISS) in Newly Diagnosed Multiple Myeloma: Analysis of Mature Data from 7077 patients collected by European Myeloma Network Within HARMONY Big Data Platform 224
CLINICAL OUTCOMES PREDICTION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THALIDOMIDE-DEXAMETHASONE AND AUTOLOGOUS STEM CELL TRANSPLANTATION BY 8-GENE SIGNATURE OF CD138+ PLASMA CELLS 221
Treatment optimization for Multiple Myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in an in vitro and ex-vivo model 219
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. 218
The role of positron emission tomography-computed tomography and magnetic resonance imaging in diagnosis and follow up of multiple myeloma. 217
Assessmen of disease ativity in multiple myeloma with FDG-PET imaging 214
Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. 210
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. 210
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma 207
Standardization of 18F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma 206
11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma. 204
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study 204
Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma 203
A Comparison of Different Staging Systems for Multiple Myeloma: Can the MRI Pattern Play a Prognostic Role? 203
Identification of a Maturation Plasma Cell Index through a Highly Sensitive Droplet Digital PCR Assay Gene Expression Signature Validation in Newly Diagnosed Multiple Myeloma Patients 202
Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma 202
Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma 202
Clinical Presentation and Long‐Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study 200
Inter-Cell Networking Profiling Enables Comprehensive Characterization of Immune-Mediated Activity of Anti-CD38 Therapy through Ex-Vivo Analysis of Multiple Myeloma Patients 200
Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens 197
Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study 197
Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma 196
Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation 194
Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis 194
First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. 193
Use of FDG-PET imaging for assessment of disease activity in patients with multiple myeloma 192
Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation. 192
Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma. 192
Complete remission upon bortezomib-dexamethasone therapy in three heavily pretreated multiple myeloma patients relapsing after allogeneic stem cell transplantation. 192
Circulating Multiple Myeloma Cells (CMMCs) as Prognostic and Predictive Markers in Multiple Myeloma and Smouldering MM Patients 189
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. 189
Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. 189
Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. 188
Contrast enhanced MRI and (18)F-FDG PET-CT in the assessment of multiple myeloma: a comparison of results in different phases of the disease 187
Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma 185
Diagnostic Innovations: Advances in imaging techniques for diagnosis and follow-up of multiple myeloma 182
Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe) 182
The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases 181
Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe) 181
Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. 181
Thalidomide maintenance in multiple myeloma: certainties and controversies. 180
Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma 179
Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma 179
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma. 177
Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents 175
PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma 175
Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission. 174
Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death. 173
Inverse probability weighting to estimate causal effect of a singular phase in a multiphase randomized clinical trial for multiple myeloma 173
HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment 172
Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency. 172
Dermoscopy of cutaneous involvement by multiple myeloma 172
HIF 1 Alpha: A Suitable Target for Multiple Myeloma 172
Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma. 171
Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy 171
European Myeloma Network Group review and consensus statement on primary plasma cell leukemia 170
Oxytocin Modulates Osteogenic Commitment in Human Adipose-Derived Stem Cells 169
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 169
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma 168
High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis 166
Comparison between 18F-FDG PET/CT and 11C-Choline PET/CT for the evaluation of multiple myeloma 165
From transplant to novel cellular therapies in multiple myeloma: EMN guidelines and future perspectives 165
High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53 165
Early use of PEPA dialyzer for light chains removal and for the recovery from myeloma cast nephropathy: A case report 165
Early Light Chains Removal and Albumin Levels with a Double Filter-Based Extracorporeal Treatment for Acute Myeloma Kidney 164
The role of imaging techniques in the management of multiple myeloma 164
IMWG consensus on risk stratification in multiple myeloma. 163
Genomic characterization of the putative myeloma stem cells clone reveals alterations possibly correlated with the origin of disease. 162
Diagnosis, treatment, and response assessment in solitary plasmacytoma: Updated recommendations from a European Expert Panel 162
18F-FDG PET/CT in myeloma with presumed solitary plasmocytoma of bone. 161
Oxytocin modulates osteogenic commitment in human adipose-derived mesenchymal stem cells 156
Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. 156
First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. 156
Multidisciplinary Management of Sternal Osteomyelitis Due to Klebsiella aerogenes after Open Heart Surgery in a Patient with Multiple Myeloma: A Case Report and Discussion of the Literature 155
Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients 155
Long-term follow-up after autologous stem cell transplantation for light- and heavy-chain deposition disease. 155
Report of the 6th International Workshop on PET in lymphoma 155
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project 154
High CNA level and over-expression of genes involved in response mechanisms to genotoxic stress characterize newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted TP53 154
Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide–dexamethasone incorporated into double autologous transplantation 154
Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group 154
Maintenance therapy in newly diagnosed multiple myeloma: current recommendations. 154
Gene expression analysis of newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted p5 153
Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma 152
Role of (18)F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. 152
Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treatedwith zoledronic acid and thalidomide-dexamethasone. 152
Extramedullary disease in multiple myeloma: a systematic literature review 151
Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials 151
Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. 151
Totale 19.296
Salva come PNG Salva come JPEG
Categoria #
all - tutte 87.839
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 87.839
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021976 0 0 0 0 0 0 0 0 0 154 139 683
2021/20222.916 250 124 186 206 274 142 82 220 139 242 550 501
2022/20233.506 352 533 161 514 230 285 112 194 554 135 265 171
2023/20241.323 83 182 97 100 116 264 77 127 34 93 84 66
2024/20255.039 209 568 422 411 522 266 429 170 135 505 403 999
2025/202612.812 1.253 1.886 1.358 1.062 1.323 736 1.212 503 2.553 926 0 0
Totale 32.617